New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer.
about
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agentsPotential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosisEpigenetics and Cellular MetabolismEffect of phenylhexyl isothiocyanate on aberrant histone H3 methylation in primary human acute leukemiaProlonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse modelModulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectivesVorinostat in solid and hematologic malignanciesTreatment outcome of thalidomide based regimens in newly diagnosed and relapsed/refractory non-transplant multiple myeloma patients: a single center experience from Thailand.Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions.Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivaxLung cancer: a modified epigenome.Hijacking HES1: how tumors co-opt the anti-differentiation strategies of quiescent cells.Epigenetics and cancer.Manipulating protein acetylation in breast cancer: a promising approach in combination with hormonal therapies?Bromodomain coactivators in cancer, obesity, type 2 diabetes, and inflammationPreclinical studies on histone deacetylase inhibitors as therapeutic reagents for endometrial and ovarian cancers.Cancer epigenetics: above and beyondCombination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancerPreclinical cancer chemoprevention studies using animal model of inflammation-associated colorectal carcinogenesis.Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphomaThe effect of CTB on P53 protein acetylation and consequence apoptosis on MCF-7 and MRC-5 cell lines.Epigenetic therapy in human choriocarcinoma.Combination of Salermide and Cholera Toxin B Induce Apoptosis in MCF-7 but Not in MRC-5 Cell Lines.Enhancing biological therapy through conditional regulation of protein stability.Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights.Cancer cells' epigenetic composition and predisposition to histone deacetylase inhibitor sensitization.Targeting histone deacetylases: development of vorinostat for the treatment of cancer.Promises and challenges of anticancer drugs that target the epigenome.Histone acetyltransferases and deacetylases: molecular and clinical implications to gastrointestinal carcinogenesis.Down-Regulation of Thioredoxin1 Is Involved in Death of Calu-6 Lung Cancer Cells Treated With Suberoyl Bishydroxamic Acid.Therapeutic strategies of drug repositioning targeting autophagy to induce cancer cell death: from pathophysiology to treatment.Class II-specific histone deacetylase inhibitors MC1568 and MC1575 suppress IL-8 expression in human melanoma cells.Selenium-containing histone deacetylase inhibitors for melanoma management.DNMT inhibitors and HDAC inhibitors regulate E-cadherin and Bcl-2 expression in endometrial carcinoma in vitro and in vivo.Interaction between ZBP-89 and p53 mutants and its contribution to effects of HDACi on hepatocellular carcinoma.Histone deacetylase inhibitor potentiates chemotherapy-induced apoptosis through Bim upregulation in Burkitt's lymphoma cells.Reactivating aberrantly hypermethylated p15 gene in leukemic T cells by a phenylhexyl isothiocyanate mediated inter-active mechanism on DNA and chromatin.Critical role of the HDAC6-cortactin axis in human megakaryocyte maturation leading to a proplatelet-formation defect.Current and Emerging Therapeutics for Cutaneous T-Cell Lymphoma: Histone Deacetylase Inhibitors
P2860
Q21198868-7CA37C34-E3BE-4F26-A26E-FC165CEE9E57Q26746099-E6907CCE-E3E3-45FE-826C-49135018DA6FQ28073039-DA658E01-C4AD-4472-A112-ACFB6990B251Q28387220-84DB4FE1-8BB3-4B9F-998E-36B7E3026044Q28743986-51552F01-37DB-42F0-B55B-0A9A3CBE7C29Q30570945-9D65AFD0-474E-4274-A396-9FDDCFB0E26AQ33385544-CB1E44E4-309B-4EA7-B404-D8E26A9684FDQ33687489-ACA7BAEC-C8D1-4158-833E-C7D71DBE32A2Q33705588-A8AE1EFD-357E-4E45-8750-A14CA982C124Q33764147-7C96B0D6-D3BF-4815-B31A-8C1EAC713780Q33781123-7FDC5DC7-2DA3-4F15-AD6E-CD63DE779D69Q33831060-8C9BD19E-D2D6-4C49-9F54-DF2D671C3F6BQ34085532-E7ABABB3-B4C0-4462-8591-663C5E34C4B0Q34417159-E32CB050-B45E-4582-ABC9-5C010BB9C388Q34513460-9B21DC7B-61C8-4111-8909-37CB57C593BCQ35739684-EDFCEBBA-70A0-4658-914C-7623B6653DDAQ35844494-51F0AD6C-402B-4EA2-AC80-4414C1B6BDD1Q36537920-E650F127-13B3-4980-B22B-3B290D78DB35Q37017072-2F1E5332-F072-4497-B0FC-FB8629DD9A5BQ37042173-335E6EFB-BF2D-40E6-BA9E-447544E6A7A4Q37108490-B7AC9804-A1FB-46D8-BDBF-7438D7B8E472Q37334277-4B6D4831-BA72-41FA-A8ED-D34939CB79FCQ37503038-5EF5217E-680E-40A9-A96B-D471529FC4D0Q37671855-27772097-8664-4D0F-9327-9E7F72A5ABA3Q37736641-D01C2456-D9AF-4CFD-8EF8-4329405A01FBQ37899757-316B4D15-810F-4B90-9DE2-C625DC6E9E5CQ37961738-6117827C-300B-40DA-9930-75BA048A5D9BQ37962596-0A9D8A76-7866-410F-BC1F-65CB1BC1A080Q37970955-BC72DF16-A161-4B92-951F-E36C0CC66714Q38828376-FE21F5BB-79C5-43C4-BD7A-348103C30D83Q39171305-02D0EB41-D13C-49CA-9AB0-4D4124761A20Q39240051-7631A6C4-FDB0-4C62-BBA6-7456F9C4AD35Q39336516-A30CE93E-35C9-4D48-A575-1E220BBABE05Q39395099-731F574A-1CCC-4912-86B0-3E0BBBAB7ADCQ39418221-FBE3180E-8044-4E33-9003-5DF3CF28E88BQ39434896-78E7976B-407E-443F-AD1A-A9E233DB91E0Q39626369-0703C8D1-09A6-446D-9DD3-4D584F8827F3Q47363826-CD2F1EED-2DF8-48CE-A711-02A35B64DB02Q58698929-FAD983C8-F850-408B-B8D5-5684F47AB11A
P2860
New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
New clinical developments in h ...... epigenetic therapy of cancer.
@en
New clinical developments in h ...... epigenetic therapy of cancer.
@nl
type
label
New clinical developments in h ...... epigenetic therapy of cancer.
@en
New clinical developments in h ...... epigenetic therapy of cancer.
@nl
prefLabel
New clinical developments in h ...... epigenetic therapy of cancer.
@en
New clinical developments in h ...... epigenetic therapy of cancer.
@nl
P2093
P2860
P921
P356
P1476
New clinical developments in h ...... epigenetic therapy of cancer.
@en
P2093
Delong Liu
Shundong Cang
P2860
P2888
P356
10.1186/1756-8722-2-22
P5008
P577
2009-06-01T00:00:00Z
P5875
P6179
1016462307